STAT
JULY 24, 2023
WILLOWBROOK, Calif. — In this neighborhood just north of Compton, Martin Luther King Jr. Community Hospital catches the light. Tall, sleek, all windows and silver finish, the hospital sits as a kind of promise to South Los Angeles. Not long ago, there was another hospital on the same property. Similar name, too: Martin Luther King Jr./Drew Medical Center.
PharmaVoice
JULY 24, 2023
Amid a wave of neuro R&D, scientists are taking an Alzheimer’s-like approach to developing the first disease-modifying treatments for Parkinson’s.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
JULY 24, 2023
A new lawsuit accuses Cigna of using an algorithm to automatically deny claims in bulk instead of individually reviewing each case, putting patients on the hook for bills the health insurer otherwise would have paid. The complaint filed Monday in the Northern District of California says Cigna uses a system called PXDX to identify discrepancies between diagnoses and the tests and services it covers for those ailments.
ALiEM - Pharm Pearls
JULY 24, 2023
Dr. Sara Krzyzaniak (EM program director at Stanford) hosts this episode with Dr. Michelle Lin (ALiEM/UCSF) featuring all-star guests Dr. Alexis Pelletier-Bui (EM associate program director at Cooper University Hospital) and Dr. Elizabeth Werley (EM program director at Penn State Hershey). Both our guests serve as key representatives on behalf of the EM specialty on the AAMC ERAS Supplemental Application Working Group and provide you with a sneak peek behind what is coming for the totally revamp
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
JULY 24, 2023
You don’t have to be an economist to understand the law of demand: The higher the price, the less likely a customer is to buy a product. This, of course, limits how much companies can charge. The law of demand applies to pharmaceuticals, but with one big difference. It’s not always the customer who decides that the price is too high. Often, it’s the insurer.
PharmaVoice
JULY 24, 2023
Commercial teams need to accept the reality of declining pharmacy reimbursement as an important variable in their go-to-market equation.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
The Pharmacist
JULY 24, 2023
Ramped up support to help smokers quit, including the prescribing of vapes, could see the UK’s smoking rate halve within the next five to 10 years, a new report has suggested. Meanwhile, the implementation of a sugar and salt reformulation tax, as well as efforts to make healthy foods more affordable and a mandatory calorie […] The post Increased support and vape use could see three million fewer smokers in UK appeared first on The Pharmacist.
STAT
JULY 24, 2023
WASHINGTON — A key House committee announced its own plans to increase health care transparency and reduce some health care costs for patients on Monday, according to bill text obtained by STAT. The House Ways & Means Committee package includes a new provision that would ensure that patients in the Medicare program pay for medicines they pick up at the pharmacy counter based on the discounted price that insurers negotiate with drugmakers, instead of higher sticker prices, starting in
BioPharma Dive
JULY 24, 2023
Treatment with magrolimab proved ineffective in a Phase 3 study in myelodysplastic syndrome, adding to doubts about so-called CD47 inhibitors as well as Gilead’s deal strategy.
STAT
JULY 24, 2023
Roche’s announcement Monday that it would pay $310 million for rights to a hypertension treatment, zilebesiran, invented by the biotech firm Alnylam is evidence of a renewed interest on the part of large pharmaceutical companies for treatments for cardiovascular disease. If things go well, Roche could pay Alnylam up to $2.8 billion in total. Heart drugs were once the most lucrative category of pharmaceuticals, but they have been eclipsed by treatments for cancer and other diseases as drug
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
BioPharma Dive
JULY 24, 2023
The Swiss pharma company is the latest large drugmaker to invest big in an experimental heart treatment, after years of prioritizing medicines for cancer and immune diseases.
STAT
JULY 24, 2023
MIAMI — Dr. Alfonso Sabater pulled up two photos of Antonio Vento Carvajal’s eyes. One showed cloudy scars covering both eyeballs. The other, taken after months of gene therapy given through eyedrops, revealed no scarring on either eye. Antonio, who’s been legally blind for much of his 14 years, can see again. The teen was born with dystrophic epidermolysis bullosa, a rare genetic condition that causes blisters all over his body and in his eyes.
BioPharma Dive
JULY 24, 2023
The shot failed to meet a key goal of Bavarian Nordic’s Phase 3 study, a finding that separates it from marketed vaccines developed by Pfizer and GSK.
STAT
JULY 24, 2023
Roche’s announcement Monday that it would pay $310 million for rights to a hypertension treatment, zilebesiran, invented by the biotech firm Alnylam is evidence of a renewed interest on the part of large pharmaceutical companies for treatments for cardiovascular disease. If things go well, Roche could pay Alnylam up to $2.8 billion in total. Heart drugs were once the most lucrative category of pharmaceuticals, but they have been eclipsed by treatments for cancer and other diseases as drug
Express Pharma
JULY 24, 2023
The mergers and acquisitions (M&A) activity of well-capitalised pharma contract manufacturing organisations (CMOs) is set to continue over the coming years despite a challenging borrowing environment due to rising inflation and interest rates, according to GlobalData. GlobalData’s latest report, ‘M&A in the Contract Manufacturing Industry: Implications and Outlook – 2023 Edition,’ reveals that the M&A activity of CMOs decreased slightly in 2022 compared to 2021.
STAT
JULY 24, 2023
This essay is adapted from “ Random Acts of Medicine: The Hidden Forces That Sway Doctors, Impact Patients, and Shape Our Health ,” out now from Doubleday. “H oney, I forgot to duck,” Ronald Reagan said to his wife as he was wheeled to the operating room of George Washington University Hospital on March 30, 1981. He had just been shot and was bleeding into his left chest.
Pharmaceutical Technology
JULY 24, 2023
Verrica has received approval from the US FDA for its YCANTH to treat molluscum in adult and paediatric patients aged two years and above.
STAT
JULY 24, 2023
Boston Children’s Hospital is located in the heart of the city’s bustling Longwood medical area. But within this dense urban landscape, there are pockets of solace for patients, their families and hospital employees. The hospital has 10 dedicated garden spaces on site. Dotted with statuary of snails, foxes, and frogs, these facilities are specially designed to accommodate the complicated needs of their patients.
European Pharmaceutical Review
JULY 24, 2023
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on approving ORSERDU ® (elacestrant) for oestrogen receptor (ER)‑positive, HER2-negative, locally advanced or metastatic breast cancer (mBC) with an activating ESR1 mutation in patients with disease progression, following at least one line of endocrine therapy including a CDK 4/6 inhibitor.
Pharma Times
JULY 24, 2023
The treatment is a monotherapy for treating adult patients with refractory or relapsed multiple myeloma - News - PharmaTimes
BioPharma Dive
JULY 24, 2023
Regulators are recognizing mass spectrometry as a powerful tool in Host Cell Protein analysis. Are you ready to implement HCP-MS?
Express Pharma
JULY 24, 2023
Lupin Digital Health and the American College of Cardiology (ACC) announced a collaboration to deliver in-home cardiovascular care with digital therapeutics (DTx) in India. This collaboration aims to accelerate the application and adoption of DTx in cardiology in India. Lupin Digital Health’s DTx platform, Lyfe, also aims to give patients and their healthcare providers tools to manage heart diseases at home and reduce rehospitalisation.
Pharma Times
JULY 24, 2023
The drug is an injectable or tablet specifically developed for HIV prevention among certain individuals - News - PharmaTimes
Express Pharma
JULY 24, 2023
AstraZeneca Pharma India has received extended indication approval from the Drugs Controller General of India (DCGI) for its drug, Dapagliflozin in the treatment of heart failure (HF) in adults. The approval is based on the detailed results from the DELIVER Phase III trial—the largest and broadest HF trial to date in patients with LVEF (left ventricular ejection fraction) >40%.
Pharmaceutical Technology
JULY 24, 2023
Shares in the company dropped by 29% despite assurances the failure would not harm its 2023 financial outlook.
BioPharma Dive
JULY 24, 2023
Outsourcing in the cell and gene therapy industry is booming and no longer considered just a “trend.
Outsourcing Pharma
JULY 24, 2023
Greenphire, provider of clinical trial financial solutions, has released its global 2023 State of Clinical Trial Patient Convenience Market Trends survey.
European Pharmaceutical Review
JULY 24, 2023
Proficiency testing programmes aim to increase the product analysis and knowledge to contribute to overall improvement in drug product quality. A paper published in Pharmaceutics has proposed how a personalised preparation quality assurance programme can achieve this when these products are developed in compounding laboratories. Quality assurance for personalised preparations According to the authors, the personalised preparation quality assurance program (PACMI) was created in 2010 at the Facul
Outsourcing Pharma
JULY 24, 2023
Phesi, a global provider of patient-centric data analytics, has released the results of its mid-year global analysis of all clinical trials conducted in 2023 to date.
PharmExec
JULY 24, 2023
Collaboration aims to help pharmaceuticals drive efficiencies and business value.
Pharmaceutical Commerce
JULY 24, 2023
Solution includes assistance with submitting regulatory submissions.
World Pharma News
JULY 24, 2023
A potent anti-cancer therapy has been created using Nobel prize-winning "click chemistry", where molecules click together like LEGO bricks, in a new study by UCL and Stanford University researchers. The study, published in Nature Chemistry, opens up new possibilities for how cutting-edge cancer immunotherapies might be built in future.
pharmaphorum
JULY 24, 2023
Designing for behaviour change: The key to success in digital health Mike.
Putting Patients First Blog
JULY 24, 2023
NHC Inaugural Health Equity Affinity Group Event Time: 1:00 - 2:30 p.m. ET Event Location: Virtual The Health Equity Affinity Group offers its patient groups, nonprofit, and professional association members the opportunity to share information, expertise, and strategic thinking on health equity-centric patient and advocacy issues. This meeting is designed to set the stage for a broader discussion, prioritize health equity issues important to the patient community, and determine actionable next s
Pharmaceutical Technology
JULY 24, 2023
In the Middle East and Africa pharmaceutical industry, there were 4 private equity deals announced in Q2 2023, worth a total value of $49.6m, according to GlobalData's Deals Database.
Expert insights. Personalized for you.
244 
Let's personalize your content